First Wave BioPharma, Inc.

FWBI | $3.02 -3.21% -2.63% 36K

(0.0% 1d) (-23.9% 1m) (6.0% 1y) (0.0% 2d) (1.7% 3d) (16.2% 7d) (Infinity% volume)
Earnings Calendar: 2022-11-14
Market Cap: $ 6,116,101
https://www.azurrx.com
Sec Filling | Patents | 12 employees

(US) AzurRx BioPharma, Inc. is a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company has a pipeline of three gut-restricted GI assets. The lead therapeutic candidate is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis and chronic pancreatitis, currently in two Phase 2 clinical trials. AzurRx is launching two clinical programs using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor, FW-420, for grade 1 Immune Checkpoint Inhibitor Colitis and diarrhea in oncology patients and FW-1022, for COVID-19 gastrointestinal infections. The Company is headquartered in Delray Beach, Florida with clinical operations in Hayward, California.

covid disease treatment phase 2 biopharma diarrhea fibrosis clinical trials test gastrointestinal trials trial pancreatic injection

add to watch list Paper trade email alert is off